Analyst Activity – Chardan Capital Lowers Its Price Target On Spring Bank Pharmaceuticals (NASDAQ:SBPH) to $30.00

Analyst Ratings For Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Story continues below

Today, Chardan Capital lowered its price target on Spring Bank Pharmaceuticals (NASDAQ:SBPH) to $30.00 per share.

There are 1 hold rating, 4 buy ratings on the stock.

The current consensus rating on Spring Bank Pharmaceuticals (NASDAQ:SBPH) is Buy (Score: 2.80) with a consensus target price of $26.25 per share, a potential 94.88% upside.

Some recent analyst ratings include

  • 7/19/2017-Cantor Fitzgerald initiated coverage with a Overweight rating.
  • 5/19/2017-JMP Securities initiated coverage with a Mkt Outperform rating.
  • 11/6/2016-Dawson James Reiterated Rating of Buy.
  • 8/19/2016-William Blair initiated coverage with a Outperform rating.

Recent Insider Trading Activity For Spring Bank Pharmaceuticals (NASDAQ:SBPH)
Spring Bank Pharmaceuticals (NASDAQ:SBPH) has insider ownership of 17.60% and institutional ownership of 9.82%.

  • On 6/27/2017 Kurt M Eichler, Director, bought 76,923 with an average share price of $13.00 per share and the total transaction amounting to $999,999.00. View SEC Filing
  • On 3/7/2017 Martin J Driscoll, Insider, bought 2,000 with an average share price of $9.44 per share and the total transaction amounting to $18,880.00. View SEC Filing
  • On 2/23/2017 Kurt M Eichler, Director, bought 1,200 with an average share price of $8.76 per share and the total transaction amounting to $10,512.00. View SEC Filing
  • On 12/15/2016 Martin J Driscoll, Insider, bought 2,000 with an average share price of $8.50 per share and the total transaction amounting to $17,000.00. View SEC Filing
  • On 11/30/2016 Martin J Driscoll, Insider, bought 2,000 with an average share price of $7.98 per share and the total transaction amounting to $15,960.00. View SEC Filing
  • On 11/9/2016 Kurt M Eichler, Director, bought 7,000 with an average share price of $8.69 per share and the total transaction amounting to $60,830.00. View SEC Filing
  • On 11/9/2016 Martin J Driscoll, Insider, bought 2,000 with an average share price of $8.84 per share and the total transaction amounting to $17,680.00. View SEC Filing

Recent Trading Activity for Spring Bank Pharmaceuticals (NASDAQ:SBPH)
Shares of Spring Bank Pharmaceuticals closed the previous trading session at 13.47 down -0.12 -0.88% with 26,594 shares trading hands.

An ad to help with our costs